LZ
Lonza Group AG
LZAGY · OTC
$67.07 +1.16% (+$0.77)
1M -9.46%
Market Cap CHF 39.2B
P/E Ratio 41.28x
Div. Yield 0.85%
ROE 10.78%
Bulios Fair Price
$34.99
47.8% downside
Current Price
$67.07
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LZAGY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
7/9Valuation
23 /100
Expensive P/B 4.29x
P/S 6.00x
P/E 41.28x
Growth
14 /100
Declining Rev. growth 1.62%
Book val. growth 4.83%
EPS growth 6.09%
Profitability
56 /100
Moderate FCF margin 2.98%
Op. margin 20.21%
Gross margin 35.35%
Quality
41 /100
Average Asset turnover 0.34x
ROA 5.00%
ROIC 6.87%
Debt
73 /100
Low Net debt/EBITDA 2.65x
Int. coverage 7.80x
Debt/Equity 0.46x
Stability
82 /100
Stable Profitable years 6
EPS volatility 48.58%
Beta 0.84x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LZAGY
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Wolfgang Wienand
Employees
16,866
Headquarters
Basel